A new platinum-based prodrug candidate: Its anticancer effects in B50 neuroblastoma rat cells
- 1 October 2018
- journal article
- research article
- Published by Elsevier in Life Sciences
- Vol. 210, 166-176
Abstract
No abstract availableKeywords
Funding Information
- University of Pavia
- Compagnia di San Paolo
This publication has 44 references indexed in Scilit:
- Redox activation of metal-based prodrugs as a strategy for drug deliveryAdvanced Drug Delivery Reviews, 2012
- Changes in mitochondrial redox state, membrane potential and calcium precede mitochondrial dysfunction in doxorubicin-induced cell deathBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2011
- PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegenerationCell Communication and Signaling, 2010
- Potent neuroprotective effects of novel structural derivatives of valproic acid: Potential roles of HDAC inhibition and HSP70 inductionNeuroscience Letters, 2010
- Chemotherapy-Induced Peripheral Neurotoxicity assessment: A critical revision of the currently available toolsEuropean Journal of Cancer, 2010
- The resurgence of platinum-based cancer chemotherapyNature Reviews Cancer, 2007
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006
- Cellular processing of platinum anticancer drugsNature Reviews Drug Discovery, 2005
- First Examples of β‐Diketonate Platinum(II) Complexes with Sulfoxide LigandsEuropean Journal of Inorganic Chemistry, 2005
- LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processingThe EMBO Journal, 2000